Lncr

الموضوع في 'السوق الأمريكي للأوراق الماليه' بواسطة SAIFY, بتاريخ ‏13 أكتوبر 2004.

  1. SAIFY

    SAIFY عضو جديد

    التسجيل:
    ‏4 أغسطس 2004
    المشاركات:
    342
    عدد الإعجابات:
    0
    Wednesday October 13, 2004 (4:16 pm ET)

    UBS Upgrades Lincare to Buy

    The therapy provider's stock rose after the government recommended a higher dispensing fee for respiratory therapies
    UBS Financial upgraded Lincare (LNCR) to buy from neutral.

    Analyst Justin Lake says according to a just-released, finalized General Accounting Office report, the Centers for Medicare and Medicaid Services has recommended a monthly dispensing fee for respiratory medications of between $55 and $64, which is at the very high end of expectations. He notes his previous estimate had included a conservative estimate regarding size of a dispensing fee in the $20-per-month range.

    Lake raised Lincare's $1.55 2005 earnings per share estimate to $1.90, and upped the $33 target to $38, (based on shares trading at 20 times the 2005 earnings per share estimate). He also raised Apria Healthcare's $1.85 2005 earnings per share estimate to $1.95.
     
  2. اول

    اول عضو محترف

    التسجيل:
    ‏14 ابريل 2004
    المشاركات:
    4,342
    عدد الإعجابات:
    0
    مكان الإقامة:
    السعودية- الرياض
    وش اسباب الارتفاع